{"References": [{"title": "Pharmacogenetic testing for CYP2C19 genotype to guide antiplatelet therapy in patients with acute coronary syndrome", "authors": "Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E", "journal": "Journal of the American College of Cardiology", "year": "2009", "volumes": "54", "first page": "2268", "last page": "2274", "DOI": "10.1016/j.jacc.2009.09.033"}, {"title": "CYP2C19 genotype and risk of adverse clinical outcomes in patients treated with clopidogrel for coronary artery disease: a meta-analysis", "authors": "Sibbing D, Stegherr J, Braun S, Mehilli J, Schulz S, Schömig A, Kastrati A", "journal": "Journal of the American College of Cardiology", "year": "2009", "volumes": "53", "first page": "1407", "last page": "1411", "DOI": "10.1016/j.jacc.2009.01.036"}, {"title": "Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA", "authors": "Johnston SC, Easton JD, Farrant M, Barsan W, Conwit R, Ferguson J, Gorelick P, Hill MD, Jauch EC, Kase CS", "journal": "New England Journal of Medicine", "year": "2012", "volumes": "367", "first page": "914", "last page": "923", "DOI": "10.1056/NEJMoa1205340"}, {"title": "Pharmacogenomic testing of CYP2C19 in patients undergoing percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial", "authors": "Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden KP, Cannon CP, Gurbel PA, Jang Y, Montalescot G", "journal": "JAMA", "year": "2019", "volumes": "321", "first page": "1044", "last page": "1054", "DOI": "10.1001/jama.2019.1517"}, {"title": "CYP2C19 genotype-guided antiplatelet therapy and outcomes after percutaneous coronary intervention: a systematic review and meta-analysis", "authors": "Sharma SV, Bhatt DL, Steg PG, Hamm CW, Gibson CM, Murphy SA, Braunwald E", "journal": "Circulation", "year": "2013", "volumes": "127", "first page": "1326", "last page": "1336", "DOI": "10.1161/CIRCULATIONAHA.112.000242"}, {"title": "Pharmacogenetic testing for CYP2C19 variants and outcomes of clopidogrel therapy in patients undergoing percutaneous coronary intervention: the COGENT-1 randomized clinical trial", "authors": "Gurbel PA, Tantry US, Bliden KP, Antonino MJ, Voskoboynik M, Miao B, Zamanian A, Kojima T, Kato S, Bliden MC", "journal": "JAMA", "year": "2012", "volumes": "307", "first page": "1375", "last page": "1384", "DOI": "10.1001/jama.2012.420"}, {"title": "CYP2C19 loss-of-function polymorphism and response to clopidogrel for prevention of cardiovascular events", "authors": "Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A", "journal": "Circulation", "year": "2009", "volumes": "119", "first page": "2578", "last page": "2585", "DOI": "10.1161/CIRCULATIONAHA.108.824704"}, {"title": "CYP2C19 genotype and the response to clopidogrel and prasugrel: a systematic review and meta-analysis", "authors": "Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP", "journal": "Circulation", "year": "2011", "volumes": "124", "first page": "1934", "last page": "1944", "DOI": "10.1161/CIRCULATIONAHA.111.032372"}, {"title": "CYP2C19 genotype and outcomes of clopidogrel treatment", "authors": "Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q", "journal": "New England Journal of Medicine", "year": "2009", "volumes": "360", "first page": "354", "last page": "362", "DOI": "10.1056/NEJMoa0809171"}, {"title": "CYP2C19 genotype and platelet reactivity after clopidogrel loading dose: a systematic review and meta-analysis", "authors": "Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Flather MD, Verheugt FW, Ardissino D", "journal": "Circulation", "year": "2010", "volumes": "122", "first page": "2673", "last page": "2681", "DOI": "10.1161/CIRCULATIONAHA.110.970345"}]}